Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShort-Term Debt issuances
Growth Metrics
Income Statement
Others
Ratios

Bristol Myers Squibb (BMYMP) Asset Writedowns and Impairment (2016 - 2025)

Bristol Myers Squibb (BMYMP) has disclosed Asset Writedowns and Impairment for 16 consecutive years, with $584.0 million as the latest value for Q4 2025.

  • Quarterly Asset Writedowns and Impairment fell 70.1% to $584.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.9 billion through Dec 2025, down 3.07% year-over-year, with the annual reading at $1.1 billion for FY2025, 62.94% down from the prior year.
  • Asset Writedowns and Impairment for Q4 2025 was $584.0 million at Bristol Myers Squibb, up from $196.0 million in the prior quarter.
  • The five-year high for Asset Writedowns and Impairment was $2.0 billion in Q4 2024, with the low at $1.0 million in Q1 2024.
  • Average Asset Writedowns and Impairment over 5 years is $299.1 million, with a median of $100.0 million recorded in 2022.
  • The sharpest move saw Asset Writedowns and Impairment plummeted 98.6% in 2021, then skyrocketed 6634.48% in 2024.
  • Over 5 years, Asset Writedowns and Impairment stood at $15.0 million in 2021, then skyrocketed by 133.33% to $35.0 million in 2022, then decreased by 17.14% to $29.0 million in 2023, then surged by 6634.48% to $2.0 billion in 2024, then crashed by 70.1% to $584.0 million in 2025.
  • According to Business Quant data, Asset Writedowns and Impairment over the past three periods came in at $584.0 million, $196.0 million, and $2.0 billion for Q4 2025, Q3 2025, and Q4 2024 respectively.